Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy
Status:
Completed
Trial end date:
2019-10-17
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c.
secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without
systemic inflammatory disease.